Printer Friendly

IDM Obtains Its First Japanese Patent.

Business Editors/Health/Medical Writers

PARIS--(BUSINESS WIRE)--June 2, 2003

IDM (Immuno-Designed Molecules), a biopharmaceutical company specialized in cellular immunotherapy, has been issued its first Japanese patent (Japan No. 541 583).

This patent, called "New antigen presenting cells, a process for preparing the same and their use as cellular vaccines" covers the preparation and use of Dendritophages(R) for therapeutic anti-cancer vaccination.

Dendritophages are one of the two families of immune therapy products called Cell Drugs developed by IDM against cancer. Dendritophages are experimental therapeutic vaccines, produced from dendritic cells loaded with tumor antigens. Studies are in progress to assess their ability to prevent the recurrence of certain cancers.

The IDM product portfolio includes Phase II therapeutic vaccines for prostate cancer and melanoma.

IDM was already issued this patent in Australia. It is pending in Canada and in Europe and will probably be authorized soon in the USA.

The IDM portfolio includes 78 issued patents (including 18 in the United States) and 91 pending patent applications (including 22 in the United States).

Jean-Loup Romet-Lemonne, President and CEO of IDM notes: "Given the length of the procedures at the Japanese patent office, we are especially pleased to obtain this first patent. It will reinforce the attraction of IDM for partnerships with Japanese companies."

IDM - The Immunogenics Company(R)

IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer.

For more information, please visit IDM's Web site,
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 2, 2003
Previous Article:Teva Announces Final Approval for Quinapril Hydrochloride Tablets.
Next Article:S&P Lowers Ratings on Four Japanese Insurers.

Related Articles
Evaluating truck tire patents.
IDM edgebander: stronger than ever.
scmegroup USA.
Barrel guarantee lasts a lifetime. (Your Business in Brief).
Innovative concepts: $11.8m for army aviation tactical modem/router.
Trans Genic Receives Japanese Patent on Cancer Diagnosis Method Using Urine Samples.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters